Skip to main content

Advertisement

Table 1 Characteristics of 80 genotype 1-infected chronic hepatitis C patients treated with pegylated interferon alpha 2b plus ribavirin combination, classified by the treatment response

From: Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment

Characteristics Total SVR Non-SVR P value
  No. = 80 No. = 39 No. = 41  
Male No. (%) 36 (45.0) 17 (43.6) 19 (46.3) 0.9821
Age (years) 57.4 ± 9.8 54.8 ± 9.3 59.8 ± 9.7 0.0133
Body Mass Index (kg/m2) 23.0 ± 3.1 23.1 ± 3.0 23.6 ± 3.4 0.7821
Alanine aminotransferase (IU/L) 89.9 ± 65.4 93.2 ± 62.8 86.5 ± 65.7 0.7832
γ-glutamyltranspeptidase (IU/L) 59.2 ± 54.0 41.2 ± 34.2 77.3 ± 33.1 0.0548
Albumin (g/dL) 4.2 ± 0.4 4.2 ± 0.4 4.0 ± 0.4 0.7105
White blood cell count (109/L) 5.6 ± 1.4 5.3 ± 1.4 5.8 ± 1.7 0.4666
Hemoglobin (g/L) 131 ± 14 133 ± 14 129 ± 14 0.2310
Platelet count (109/L) 161 ± 51 167 ± 45 156 ± 55 0.1576
Creatinine (mg/dL) 0.71 ± 0.14 0.69 ± 0.16 0.70 ± 0.15 0.3376
Creatinine clearance (mL/min) 98.8 ± 27.6 100.2 ± 28.7 99.3 ± 32.3 0.4102
Histological cirrhosis No. (%) 6 (7.5) 2 (5.1) 4 (9.7) 0.6758
  1. HCV, hepatitis C virus
  2. Data is shown as the mean ± standard deviation.
  3. SVR means a sustained virological response, which is defined as serum HCV RNA undetectable at 24 weeks after the end of treatment.